RECURRENT FALLOPIAN TUBE CARCINOMA

This early-stage study tests a drug called talazoparib together with radiation therapy for people whose gynecologic cancer (like ovarian, endometrial, or cervical) has returned after previous treatment. The main goal is to find the safest dose and see how well the combination wor…

This study tests a personalized vaccine made from a patient's own white blood cells, combined with an immunotherapy drug (pembrolizumab), for people with ovarian cancer that has returned. The vaccine targets a protein found on many ovarian cancer cells, training the immune system…

This early-stage study tests a new treatment for ovarian cancer that has come back or not responded to standard therapy. The treatment uses a patient's own immune cells (T cells) that are trained in a lab to recognize and attack a protein called MUC1 found on cancer cells. The ma…

This study tests whether adding an experimental drug (APL-2) to standard immunotherapy (pembrolizumab) and/or a targeted therapy (bevacizumab) can better control fluid buildup and tumor growth in people whose ovarian, fallopian tube, or peritoneal cancer has returned. About 60 ad…

This study tests whether adding an experimental drug (CDX-1140) to two standard immunotherapies (pembrolizumab and bevacizumab) can shrink tumors in people whose ovarian cancer has returned. About 80 adults with specific types of recurrent ovarian, fallopian tube, or peritoneal c…

This study is for women whose ovarian or endometrial cancer has returned or not gone away and has a specific change in the RAS gene. It compares taking two drugs (selumetinib and olaparib) versus selumetinib alone. The goal is to see if the combination can shrink tumors or keep t…

This early-phase study tests a radioactive tracer called [18F]FTT to see if it can help PET/CT scans find more tumor cells in people with solid tumors, including ovarian, breast, and fallopian tube cancers. About 300 participants will receive the tracer and undergo imaging. The g…

This study tests whether a personalized activity program using a Fitbit can help people with ovarian or endometrial cancer exercise more and improve their quality of life. About 120 participants will either get the program or standard advice. The goal is to see if the program hel…

This study aims to understand why some people who have had ovarian or other solid cancers later develop blood cancers. Researchers will follow 2,000 participants to identify genetic and environmental risk factors. The goal is to improve monitoring and prevention for cancer surviv…

This study screens patients with advanced solid tumors to find genetic changes in their cancer cells. Based on those results, patients may be matched to a treatment trial that targets their specific tumor mutations. The goal is to improve how doctors choose combination therapies …